The angiopoietins Ang1 (ANGPT1) and Ang2 (ANGPT2) are secreted factors that bind to the endothelial cell-specific receptor tyrosine kinase Tie2 (TEK) and regulate angiogenesis. Ang1 activates Tie2 to promote blood vessel maturation and stabilization.
͵

Introduction
The Angiopoietin/Tie2 signaling system is essential for vascular development and function (1). Tie2 is an endothelial cell-specific tyrosine kinase receptor for the Angiopoietin ligands, the best studied of which are Angiopoietin-1 (Angpt1; Ang1) and Angiopoietin-2 (Angpt2; Ang2). Ang1 is a strong Tie2 agonist that is produced primarily by perivascular cells, and Ang1/Tie2 signaling is believed to promote blood vessel maturation and stabilization (1-6). In contrast, Ang2 is produced primarily by the endothelial cells in remodeling blood vessels (1, 7, 8) and is believed to function largely as a Tie2 antagonist to promote tumor angiogenesis and inflammation (1, (7) (8) (9) (10) (11) (12) (13) . Ang2 expression is upregulated in a wide range of human cancers (14) (15) (16) (17) (18) (19) (20) , and recent preclinical studies employing Ang2 inhibitors and Ang2 knockout mice have established that Ang2 is important for tumor angiogenesis and tumor growth (21-31).
The dominant model for the role of Ang2 in tumors proposes that Ang2 competes with Ang1 for Tie2 binding, thereby inhibiting Tie2 activity (1, 7, 13) . The loss of Tie2 signaling is thought to lead to vessel destabilization, which facilitates VEGF-dependent angiogenesis (1, 7, 13) . Consistent with this model, a number of papers have shown that overexpression of Ang2 can disrupt the tumor vasculature (32-34). However, several studies indicate that in certain settings Ang2 can activate . Furthermore, recent data indicate that the effects of an Ang2-specific blocker on tumor growth are not reversed by co-treatment with an Ang1-specific blocker, suggesting that Ang2 does not function to inhibit Ang1 action (22, 28) . Thus, the mechanism of Ang2 signaling in tumors remains controversial and data that directly link Ang2 blockade to changes in Tie2 activity are lacking.
While Ang2 inhibition reduces the growth of a broad range of tumors in preclinical models, the effects are relatively modest, with only partial growth inhibition usually observed (21, 24, 27, 30) . However, treatment with a combination of Ang2 and VEGF blockers provides better inhibition of tumor growth than either single agent in a number of tumor models (21) (22) (23) (24) (25) 30) . However, several of the VEGF blockers used in the published combination experiments are of uncertain specificity (21, 24), or only block human, but not mouse, VEGF (22, 24, 30) . Furthermore, in most cases it was not demonstrated that the VEGF and Ang2 blockers were used at doses that provide maximal Ͷ inhibition of each individual pathway (21) (22) (23) (24) 30) . Thus, it remains to be convincingly demonstrated that blockade of Ang2 provides additional antitumor benefit under conditions where VEGF activity is completely and specifically blocked.
To investigate the molecular mechanism of Ang2 signaling in tumors, we have generated a fully-human antibody (REGN910) that is completely specific for Ang2. Here we provide strong evidence that Ang2 is a Tie2 activator in tumors and demonstrate that combination treatment with REGN910 plus ZALTRAP® (commonly known in the literature as VEGF Trap or aflibercept), a highly specific blocker of both human and mouse VEGF, inhibits tumor angiogenesis and tumor growth more potently than saturating doses of either single agent. Our findings, in contrast to the current model, indicate that Ang2 plays a protective rather than a destabilizing role in tumor endothelial cells. Furthermore, our data indicate that Ang2 signaling limits the antivascular effects of VEGF inhibition, suggesting that blockade of Ang2 might enhance the clinical benefits provided by anti-VEGF therapies.
Materials and Methods
Generation of human antibodies against Ang2. VelocImmune ® mice (with genes encoding human immunoglobulin heavy and kappa light chain variable regions) in which the Ang2 gene was replaced with the mouse Ang1 cDNA were immunized with recombinant human Ang2 fibrinogen-like domain. Spleens were harvested for generation of hybridomas or for direct isolation of antigen-positive splenocytes. The cloned human immunoglobulin variable region genes from antibodies exhibiting the desired characteristics were joined to human IgG1 constant region genes for production in CHO cells. REGN910 was selected as a lead antibody from more than 1000 antigen-positive clones, based on in vitro biochemical properties as well as the ability to inhibit tumor xenograft growth. The methods used to characterize the biochemical properties of REGN910 are described in detail in the Supplementary Methods. 
Tumor xenograft growth studies
Analysis of tumor vascularity, perfusion and gene expression
Tumor sections were stained with a rat anti-murine CD31 (Pecam1) antibody (BD Pharmingen) to visualize blood vessels using standard methodology. Tumor cell death was assessed by TUNEL stain with the In Situ Cell Death Detection Kit (Roche). Tumor perfusion was assessed by contrast enhanced micro-ultrasound imaging, using
MicroMarker™ contrast agent and a Vevo® 2100 Micro-Ultrasound Imaging System (VisualSonics Inc, Toronto, Canada). Tumor gene expression was measured by real-time PCR under standard Taqman® conditions on the ABI 7900HT instrument using the automatic setting for determining the threshold cycle. Additional detail on these methods is contained in the Supplementary Methods.
Results
A fully-human monoclonal antibody, REGN910, binds Ang2 with high affinity and specificity and inhibits Ang2/Tie2 signaling Human antibodies against Ang2 were generated as described in the Materials and
Methods. The lead antibody REGN910 (selected from more than 1,000 antigen-positive clones) exhibits high affinity binding to human, monkey and mouse Ang2 (K D ~18 pM for human Ang2), but does not bind to Ang1 at all, as measured in SPR Biacore experiments (Supplementary Table 1 ). Furthermore, REGN910 blocked the binding of Ang2 to Tie2 with an IC 50 of ~60 pM, but had no effect on Ang1/Tie2 binding, even at a high antibody concentration (Fig. 1A) . Thus, REGN910 is a potent and specific inhibitor of the Ang2/Tie2 interaction.
To confirm that REGN910 inhibits Ang2 signaling, we tested its ability to inhibit Ang2-dependent Tie2 phosphorylation in human umbilical vein endothelial cells (HUVECs) in which Ang2 expression is induced by the transcription factor FOXO1 (35).
HUVECs expressing elevated levels of Ang2 exhibited a marked increase in Tie2 phosphorylation (Fig. 1B, lane 2) , which was completely inhibited by the addition of REGN910 at concentrations of 2 nM or above (Fig. 1B , lanes 4-6), confirming that REGN910 inhibits autocrine Ang2-mediated Tie2 activation. Consistent with its inability to bind Ang1, REGN910 had no effect on Ang1-dependent Tie2 phosphorylation (Fig.   1C ).
REGN910 inhibits tumor xenograft growth and decreases tumor vascularity
To assess the effect of REGN910 on tumor growth, Colo205 (colorectal), PC3
(prostate) and A431 (epidermoid) tumor xenografts were grown in immunocompromised mice. As shown in Supplementary significantly inhibited the growth of all three tumors, with maximal efficacy achieved with the 2.5 mg/kg dose (50%, 70% and 54% inhibition of Colo205, PC3 and A431 tumor growth, respectively; Fig. 2A-2C ). Thus, REGN910 as a monotherapy significantly delays the growth of multiple tumor xenografts.
The inhibition of tumor growth by REGN910 was associated with a significant decrease in tumor vascularity (Fig. 2D) , consistent with previous reports that Ang2 blockade inhibits tumor angiogenesis (21) (22) (23) (24) (28) (29) (30) (31) . To assess whether the decrease in tumor vascularity reflects increased endothelial cell apoptosis and/or decreased endothelial cell proliferation, we performed immunohistochemistry to quantitate dualpositive CD31/TUNEL and CD31/BrdU pixels following REGN910 treatment. As shown in Supplementary Fig. 1 , REGN910 treatment modestly increased endothelial cell apoptosis and decreased endothelial cell proliferation. While the changes observed at a single time point (10 day treatment) were not statistically significant (due to high intertumor variability), our data suggests that the decrease in tumor vascularity observed following Ang2 blockade might be attributable to modulation of both endothelial cell apoptosis and proliferation, consistent with earlier reports (22, 29, 31) . Furthermore, consistent with previous studies (23, 26, 28) , REGN910 treatment significantly increased the percentage of blood vessels that were closely associated with pericytes ( Supplementary Fig. 2 ). target genes in tumors (see below). Ang1 completely reversed the inhibitory effect of REGN910 on tumor growth in both models (Fig. 3A, 3B ), indicating that Ang2 functions ͺ as a Tie2 agonist in these settings. Ang1 did not by itself increase tumor growth versus Fc control treatment (Fig. 3A, 3B) , presumably because the level of Tie2 phosphorylation in these tumors is already sufficiently high to support maximal tumor growth. Ang1 also blunted the decrease in tumor vascularity caused by REGN910 (Fig. 3C ), indicating that Ang1-mediated rescue of tumor growth reflects an effect on the tumor vasculature.
Ang2 functions as a Tie2 agonist in tumors
To provide further support for the hypothesis that Ang2 is a Tie2 agonist in tumors,
we investigated the effects of REGN910 on the expression of Tie2 target genes. Our ͳͲ modest decreases in tumor perfusion at this early time point, the combination of REGN910 plus ZALTRAP® had a substantially greater effect, causing a 70% reduction in perfusion ( Figure 6B, left) . Importantly, none of the treatments had an effect on blood vessel perfusion in adjacent normal skin (Fig. 6B, right) , indicating that the actively remodeling blood vessels in tumors are preferentially dependent on Ang2 and VEGF.
The more potent effect of the REGN910 plus ZALTRAP® combination on tumor perfusion is consistent with the more pronounced decrease in tumor vascularity that is observed following combination treatment as compared to the single agent treatments.
Finally, to assess the effect of decreased vascularity and perfusion on tumor cells, we used the TUNEL assay to assess tumor cell death at 72 hours after treatment. While both REGN910 and ZALTRAP® as single agents caused an increase in tumor cell death versus control, the combination treatment had a much more dramatic effect, promoting extensive tumor cell death (Fig. 6C, left) . On average, ~75% of the tumor area in the combination treatment group was TUNEL-positive ( (Fig. 5A) . Interestingly, at an earlier time point (24 hours), we were able to detect an increase in endothelial cell death in tumors treated with the combination (Supplementary Fig. 4 ). While the overall percentage of dead endothelial cells detected at this single time point was quite low (< 1% of the total endothelial cells), this finding suggests the possibility that the more potent effect of the combination treatment on tumor vascularity is at least partly due to increased endothelial cell death. Together, our results indicate that both Ang2 and VEGF significantly contribute to tumor angiogenesis and that combined blockade of both factors results in more potent inhibition of tumor vascular function and of tumor growth than blockade of either factor individually. ͳͳ
Discussion
In this manuscript we employed a novel, fully-human Ang2 antibody, REGN910, to investigate the mechanism of Ang2 signaling in tumors. The dominant model for Ang2 function in tumors proposes that Ang2 inhibits Tie2 signaling and destabilizes tumor blood vessels, thereby facilitating VEGF-dependent angiogenesis (1, 7, 13). However, in this study we show that systemic Ang1 reverses the effects of REGN910 on tumor growth and vascularity and that REGN910 increases the expression of genes that are repressed by Tie2 activation. These findings strongly suggest that REGN910 decreases Tie2 signaling in tumors and therefore that Ang2 functions as a Tie2 agonist.
Our previous work established that Ang2 expression is induced in cultured endothelial cells by FOXO transcription factors in response to low Akt activity, and that in this setting Ang2 activates Tie2 (35, 42). These findings suggested that Ang2 induction is an adaptive mechanism to restore Tie2/Akt signaling. Based on the current study, we propose that in tumors , Ang2 functions to activate Tie2, particularly in endothelial cells that are not exposed to significant levels of pericyte-derived Ang1 (likely the majority of tumor endothelial cells) (see Fig. 7 Although our data show that the overall effect of Ang2 blockade in tumors is a decrease in Tie2 activity, some of the morphological effects of Ang2 inhibition (e.g., increased pericyte association, endothelial junctional maturation (28)) are likely to reflect an increase in Tie2 signaling in a subset of endothelial cells. One potential explanation for this apparent discrepancy is that in the subset of tumor endothelial cells exposed to both Ang2 and to pericyte-derived Ang1, specific blockade of the weaker agonist Ang2 would lead to greater Tie2 activity (Fig. 7) . This subset of endothelial cells may represent a relatively small percentage of the total, since published reports (23, 26, 28) and the data in Supplementary Fig. 2 suggest that only ~25% of the vessels in tumor ͳʹ xenografts are closely associated with pericytes. Thus, the increased pericyte association observed following Ang2 blockade is not necessarily inconsistent with the fact that the overall effect of Ang2 blockade is a decrease in Tie2 signaling.
Interestingly, a recent report suggests the possibility that Ang2 can promote angiogenesis via binding to integrins on endothelial cells that express low levels of Tie2 (44). However, we believe that in our tumor models, the inhibition of tumor growth/angiogenesis that results from Ang2 blockade is attributable to decreased Tie2 activity, since these effects are reversed by the Tie2 agonist Ang1 and they are accompanied by changes in expression of well-established Tie2 target genes.
The fact that systemic delivery of exogenous Ang1 reverses the tumor growth inhibition caused by REGN910 suggests the possibility that Ang1, if present at high levels, might promote resistance of tumors to Ang2-specific blockers. However, published reports have shown that an Ang1-specific blocker has no effect on tumor growth (22, 28) and that dual Ang1/Ang2 blockade provides at best a marginal and inconsistent additional benefit over specific Ang2 blockade in one tumor xenograft model (Colo205) (22, 28). Thus, the currently available data suggest that endogenous tumor Ang1 does not compensate in a significant way for the inhibition of Ang2.
While Ang2/Tie2 signaling has been mostly studied in endothelial cells, recent work has identified a population of monocytes that express Tie2 (45). These cells, known as Hearts were excised at 4 or 8 hours after treatment, RNA was isolated and the levels of Ang2 and ESM1 RNA (normalized to gapdh) were determined by TaqMan real-time PCR. The bar graphs depict the relative Ang2 or ESM1 RNA levels versus the Fc control group (assigned a value of 1.0). Error bars represent SD. The differences in Ang2 and ESM1 RNA levels between the Fc and Ang1-treated groups were statistically significant at both 4 and 8 hours by t-test (* P < 0.05, ** P < 0.01). B) Cultured rat heart microvessel endothelial cells were either untreated or treated with Ang1 for 2 hours. 
